Skip to main content
NCBI home page
The BMJ logoLink to The BMJ
. 1992 Oct 3;305(6857):804–807. doi: 10.1136/bmj.305.6857.804

Computer system for assisting with clinical interpretation of tumour marker data.

M S Leaning 1, S Gallivan 1, E S Newlands 1, J Dent 1, M Brampton 1, D B Smith 1, K D Bagshawe 1
PMCID: PMC1883503  PMID: 1330140

Abstract

OBJECTIVE--To design and evaluate a computer advisory system for the treatment of gestational trophoblastic tumour. DESIGN--A comparison of clinicians' treatment decisions with those of the computer system. Two datasets were used: one to calibrate the system and one to independently evaluate it. SETTING--Department of medical oncology. PATIENTS--Computerised records of 290 patients with low risk gestational trophoblastic tumour for whom the advisory system could predict the adequacy of treatment. The calibration set comprised patients admitted during 1979-86(227) and the test set patients during 1986-89(63). MAIN OUTCOME MEASURES--The system's accuracy in predicting need to change treatment compared with clinicians' actions. The mean time faster that the system was in predicting the need to change treatment. RESULTS--On the calibration dataset the system was 94% (164/174) accurate in predicting patients whose treatment was adequate, recommending change when none occurred in only 10 (6%) patients. In patients whose treatment was changed the system recommended change earlier than clinicians in 39/53 cases (74%), with a mean time advantage of 14.9 (SE 2.02) days. On the test dataset the system had an accuracy of 91% (31/34) in predicting treatment adequacy and a false positive rate of 9% (3/34). The system recommended change earlier than clinicians in 22/29 cases (76%), with a mean time advantage of 12.5 (2.22) days. CONCLUSIONS--The computer advisory system could improve patient management by reducing the time spent receiving ineffective treatment. This has implications for both patient time and clinical costs.

Full text

PDF
804

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bagshawe K. D., Dent J., Newlands E. S., Begent R. H., Rustin G. J. The role of low-dose methotrexate and folinic acid in gestational trophoblastic tumours (GTT). Br J Obstet Gynaecol. 1989 Jul;96(7):795–802. doi: 10.1111/j.1471-0528.1989.tb03318.x. [DOI] [PubMed] [Google Scholar]
  2. Bagshawe K. D. Risk and prognostic factors in trophoblastic neoplasia. Cancer. 1976 Sep;38(3):1373–1385. doi: 10.1002/1097-0142(197609)38:3<1373::aid-cncr2820380342>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  3. Hawkins R. E., Roberts K., Wiltshaw E., Mundy J., Fryatt I. J., McCready V. R. The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma. Br J Obstet Gynaecol. 1989 Dec;96(12):1395–1399. doi: 10.1111/j.1471-0528.1989.tb06301.x. [DOI] [PubMed] [Google Scholar]
  4. Hunter V. J., Daly L., Helms M., Soper J. T., Berchuck A., Clarke-Pearson D. L., Bast R. C., Jr The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. Am J Obstet Gynecol. 1990 Oct;163(4 Pt 1):1164–1167. doi: 10.1016/0002-9378(90)90680-6. [DOI] [PubMed] [Google Scholar]
  5. Lange P. H., Vogelzang N. J., Goldman A., Kennedy B. J., Fraley E. E. Marker half-life analysis as a prognostic tool in testicular cancer. J Urol. 1982 Oct;128(4):708–711. doi: 10.1016/s0022-5347(17)53149-3. [DOI] [PubMed] [Google Scholar]
  6. Picozzi V. J., Jr, Freiha F. S., Hannigan J. F., Jr, Torti F. M. Prognostic significance of a decline in serum human chorionic gonadotropin levels after initial chemotherapy for advanced germ-cell carcinoma. Ann Intern Med. 1984 Feb;100(2):183–186. doi: 10.7326/0003-4819-100-2-183. [DOI] [PubMed] [Google Scholar]
  7. Rustin G. J., Gennings J. N., Nelstrop A. E., Covarrubias H., Lambert H. E., Bagshawe K. D. Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group. J Clin Oncol. 1989 Nov;7(11):1667–1671. doi: 10.1200/JCO.1989.7.11.1667. [DOI] [PubMed] [Google Scholar]
  8. Toner G. C., Geller N. L., Tan C., Nisselbaum J., Bosl G. J. Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors. Cancer Res. 1990 Sep 15;50(18):5904–5910. [PubMed] [Google Scholar]
  9. Vogelzang N. J., Lange P. H., Goldman A., Vessela R. H., Fraley E. E., Kennedy B. J. Acute changes of alpha-fetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors. Cancer Res. 1982 Nov;42(11):4855–4861. [PubMed] [Google Scholar]
  10. van der Burg M. E., Lammes F. B., van Putten W. L., Stoter G. Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy. Gynecol Oncol. 1988 Jul;30(3):307–312. doi: 10.1016/0090-8258(88)90244-2. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES